CoreValve
Established: 2001
Investors: Apax Partners, Healthcap Venture Capital, Maverick Capital, Sofinnova Ventures
Core Valve has already helped 25,000 heart disease sufferers worldwide with its pioneering Transcatheter Aortic Valve Replacement. The device, which can be inserted via a small incision in the leg, neck or chest and guided into place, offers a minimally invasive alternative to open-heart surgery.
The France-founded company was acquired by US medical device maker Medtronic in 2009 for $700 million1 and has continued to gather data from long-running trials to highlight its success. A five-year study into Medtronic’s valve replacement technologies, which aim to reduce hospital stays and speed up recovery times, showed that safety is on a par with open-heart surgery, underlining the benefits to patients and healthcare systems alike2.
Transcatheter Aortic Valve Replacement (TAVR) Implant Animation for the Medtronic Evolut (Video – 03:15)
25,000+
patients treated
$63m
raised in VC funding
$700m
acquisition by Medtronic in 2009
Key achievements
Over 25,000 patients treated with Core Valve’s minimally invasive heart valve replacement
Five-year study demonstrated safety on a par with open-heart surgery
Acquired by Medtronic for $700m in 2009
Funding history
Raised $63m in VC funding3
Find out more
1. https://tracxn.com/d/companies/corevalve.com
2. https://www.fiercebiotech.com/medtech/tct-2021-medtronic-s-tavr-valve-safety-par-open-surgery-after-5-years
3. Preqin
Investors
